# ZUMA-7 (NCT03391466)

> Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03391466
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions: Axicabtagene Ciloleucel; Platinum-containing Salvage Chemotherapy; Cyclophosphamide; Fludarabine
- Enrollment: 359
- Primary outcome: Event Free Survival (EFS) Per Blinded Central Assessment

## Commentary we found

- YouTube: 84
- X threads: 84
- Podcasts: 82

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-7-nct03391466

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03391466", "email": "<work email>"}; the inbox owner confirms by the emailed link.